23 protocol(s) meet the specified criteria
Disease Site: Bones and Joints
Protocol No.TitleStatus
10-CBAA multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indicationsOpen
15-MMUDA Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic MalignanciesOpen
20120139 A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials Open
201312100A Blinded, Prospective Non-Interventional Observational Study for the Evaluation of a GVHD Negative Outcome Score (GNOS) in Matched Unrelated or Haploidentical Hematopoietic Stem Cell TransplantOpen
A-TREATAmerican Trial Using Tranexamic Acid in Thrombocytopenia (A-TREAT) Open
A051301 A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo In Patientswith Relapsed or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype Open
AEWS1221Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing SarcomaOpen
BMT-CTN-1301A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host DiseaseOpen
COG-AOST06B1A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma SpecimensOpen
COG-AOST1321Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory OsteosarcomaOpen
COGAEWS1031A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing SarcomaOpen
EBV-CTL-301Multicenter, Open-Label, Phase 3 Trial of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Allogeneic Hematopoietic Cell Transplant (alloHCT) Patients with EBV-Associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) after Failure of RituximabOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
LCCC1511Skin Tissue Banking ProtocolOpen
LCCC1530Fitness in Allogeneic Stem Cell Transplantation (FAST)Open
LCCC1530AFitness in Allogeneic Stem Cell Transplantation (FAST) Sub-StudyOpen
LCCC1602Health services use and social outcomes of adult survivors of childhood cancerOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NG-BSP-600-001Evaluation of the CytoRADx System as a Biodosimeter with Human Subjects Receiving Radiation TherapyOpen
PCYC-1140-IMA Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)Open
TV44688-ONC-30054A Single-Arm Study of the Effect of a 5-day Regimen of Tbo-Filgrastim 10 μg/kg of Body Weight Administered Subcutaneously on Peripheral Stem Cell Mobilization in Healthy DonorsOpen
VEG116731A Phase II Study of Pazopanib (GW786034, NSC# 737754) in Children, Adolescents and Young Adults with Refractory Solid TumorsOpen
X16032Ixazomib for Treatment of Chronic Graft vs. Host DiseaseOpen